Stryker has announced research, development and innovation investments worth around $225 million in three of its Irish facilities. The company's instruments innovation center, AMagine Institute and neurovascular business will see the investments.
Orchestra BioMed and Tokyo-based Terumo have teamed up on the development and commercialization of Orchestra's Virtue sirolimus-eluting balloon in peripheral cardiovascular and coronary interventions. Terms of the agreement include the payment of $30 million upfront and a $5 million equity commitment plus potential milestone payments from Terumo to Orchestra.
Acumed has paid an undisclosed amount for Radicle Orthopaedics' RASL Repair System, a device intended for treating the scapholunate ligament in the wrist. The acquisition is intended to expand Acumed's hand and wrist portfolio, which includes the the Acutrak 2 Headless Compression Screw.
Zimmer Biomet has tapped orthopedic surgeon Andrew Freiberg to serve as its chief medical officer, a newly created position in the company. Freiberg, an adult reconstructive surgery expert with a focus on hip and knee arthroplasty, has led Massachusetts General Hospital's hip and knee service for more than two decades.
The New York State Department of Health has granted Bio-Techne a clinical laboratory permit for its liquid biopsy-based ExoDx Prostate IntelliScore test, which helps determine whether patients who have an ambiguous prostate specific antigen test result need a prostate biopsy. The test is now available in all 50 states as a result of the decision.
CyberMDX researchers have found that Becton Dickinson's Alaris Gateway Workstation infusion pump could be remotely controlled by installing malicious firmware on its onboard computer, and its monitoring and configuration interfaces could also be accessed by an attacker via a web browser.
The device manufacturer has advised pump owners to update the devices with the latest firmware, which comes with fixes for the two vulnerabilities.
Dexcom CEO Kevin Sayer said a number of G6 diabetes system upgrades, including a direct-to-Apple Watch version, will be released by the company throughout the next year. The company is also developing the G7 system in partnership with Alphabet subsidiary Verily and is looking to launch the G6 system to the Medicare market.
The FDA has granted Materialise clearance to market its Mimics Enlight cardiovascular planning software, which facilitates planning of transcatheter mitral valve replacement procedures by allowing the production of 3D patient-specific models.
European regulators have granted eMurmur CE mark approval for its sensor that detects heart murmurs using machine learning, a web portal and a mobile app. The mobile device, which uses cloud technology and a third-party electronic stethoscope, also determines when a heart murmur is absent.
The AdvaMed Purchasing Group is a new member-only benefit that helps companies purchase the very best goods and services from nationally recognized suppliers at the very best cost, using a trusted and proven vetting system and the collective purchasing power of our membership. Participation is free for AdvaMed members, and there are no minimum commitments. Get started today.